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2Abstract
Increased levels of the chemokine CCL2 in cancer patients are associated with poor prognosis. 
Experimental evidence suggests that CCL2 correlates with inflammatory monocyte recruitment
and induction of vascular activation; but the functionality remains open. Here, we show that 
endothelial Ccr2 facilitates pulmonary metastasis using an endothelial-specific Ccr2-deficient 
mouse model (Ccr2ecKO). Similar levels of circulating monocytes and equal leukocyte 
recruitment to metastatic lesions of Ccr2ecKO and Ccr2fl/fl littermates were observed. The 
absence of endothelial Ccr2 strongly reduced pulmonary metastasis, while the primary tumor 
growth was unaffected. Despite a comparable cytokine milieu in Ccr2ecKO and Ccr2fl/fl
littermates the absence of vascular permeability induction was observed only in Ccr2ecKO mice.
CCL2 stimulation of pulmonary endothelial cells resulted in increased phosphorylation of 
MLC2, endothelial cell retraction and vascular leakiness that was blocked by an addition of 
CCR2 inhibitor. These data demonstrate that endothelial CCR2 expression is required for 
tumor cell extravasation and pulmonary metastasis.
Implications: Findings provide mechanistic insight into how CCL2-CCR2 signaling in 
endothelial cells promotes their activation through myosin light chain phosphorylation resulting 
in endothelial retraction and enhanced tumor cell migration and metastasis.
3Introduction
Metastasis is the main reason for cancer-related fatalities. Hematogenous metastasis is a 
multistep process depending on interactions of disseminated tumor cells with the 
microenvironment (e.g. platelets and leukocytes) and ultimately with the endothelium in distant 
organs (1, 2). Tumor cell migration through vascular barriers is promoted by the recruitment of 
monocytic cells that contribute to formation of a metastatic niche (3-5). Pro-inflammatory 
chemokines, particularly CCL2, were linked to the accumulation of CCR2-expressing 
inflammatory monocytes during metastasis (6-9). High levels of pro-inflammatory chemokines, 
e.g. CCL2 and CCL5, in circulation are associated with poor prognosis for cancer patients 
(reviewed in 10). Therefore, many studies explored the genetic and pharmacological inhibition 
of the CCL2-CCR2 axis as a mean to impair monocyte recruitment to metastatic sites. 
Whereas CCL2 clearly potentiates monocyte recruitment in vitro (11), other tumor- or stroma-
derived chemokines (e.g. CCL3, CCL5) may contribute to this process in vivo (4, 10). 
Similarly, inflammatory monocytes, defined as Ly6Chi and CCR2+ cells, express several 
chemokine receptors, e.g. CCR1, which can facilitate chemokine-driven monocyte recruitment 
to sites of inflammation or tumorigenesis (12). For instance, CCR2 was not required for 
inflammatory monocyte recruitment in an acute inflammation model (13, 14).
The CCL2-CCR2 chemokine/chemokine receptor axis is required for the egress of 
inflammatory monocytes from the bone marrow to the circulation during homeostasis and 
inflammation (13, 14). Thus, systemic Ccr2 deficiency or a treatment with CCL2 neutralizing 
agents resulted in reduced circulating monocyte numbers (8, 13). In addition, increased 
circulating serum levels of Ccl2 resulted in reduced responsiveness of blood cells to other 
chemokines (15). Similarly, anti-CCL2 antibody treatment of rheumatoid arthritis patients 
4results in higher CCL2 serum levels and worsening of the disease symptoms (16).
There is accumulating evidence that CCR2 on stromal cells, particularly on 
endothelium, has a physiological role during inflammation (17, 18). Activation of brain 
endothelial CCR2 by CCL2 induced vascular leakiness (18) and regulated macrophage 
transendothelial migration (17). Furthermore, CCR2-mediated endothelial activation was 
linked to tumor-associated angiogenesis (19). While tumor cell-derived CCL2 expression is 
associated with enhanced metastasis, the analysis of metastatic lungs revealed that recruited 
monocytes and endothelial cells significantly contribute to an increased pool of CCL2 at 
metastatic sites (5). Recently, endothelial activation by CCL2 was directly linked to tumor cell-
induced lung vascular permeability (9, 20); however, the underlying mechanism remains 
unclear.
Endothelial retraction is an essential step in metastasis both during intravasation and 
extravasation. Phosphorylation of VE-cadherin has been shown to be essential for initiation of 
transendothelial migration of leukocytes (21) and also tumor cells (5). Recent data show that 
VE-cadherin rearrangement in endothelial cells is associated with enhanced phosphorylation of 
myosin light chain 2 (MLC2) during angiogenesis (22). In addition, inhibition of VE-cadherin 
rearrangement, which is associated with reduced MLC2 phosphorylation, in endothelial cells 
maintains endothelial barrier function during inflammation (23).  
Tumor-derived chemokines actively shape the tumor microenvironment and directly 
affect various cell types both at primary and at metastatic sites (10, 24). Here we show that 
CCR2-signalling in lung endothelial cells induces cytoskeletal rearrangement resulting in 
enhanced vascular permeability required for monocyte-assisted tumor cell transendothelial
migration and metastatic initiation.
5Materials & Methods
Cell culture
Primary lung endothelial cells were isolated by immuno-magnetic selection using anti-CD31 
antibody and cultivated as described previously (9). Bone marrow monocytes were isolated 
from femur and tibia followed by magnetic anti-CD115 purification as described previously (5).
Mouse carcinoma cell lines MC-38GFP and LLC1.1 were grown as described (5). 
Immortalized mouse brain endothelial cell line; bEnd.3 (from ATCC) was grown in 
DMEM/10% FCS supplemented with 1x NEAA and 1mM Na-Pyruvate.
Mice
All animal experiments were performed according to the guidelines of the Swiss Animal 
Protection Law, and approved by the Veterinary Office of Kanton Zurich. C57BL/6J (wt) mice 
as well as systemic Ccr2-deficient mice, B6.129S4-Ccr2<tm1Ifc/J>, were purchased from The 
Jackson Laboratory. VE-cad-Cre/Ccr2fl/fl mouse (hereafter Ccr2ecKO mouse) was generated by
breeding the Ccr2fl/fl mouse (25) (obtained from M. Pasparakis) with the VE-cadherin-Cre 
mouse, B6.FVB-Tg(Cdh5-cre)7Mlia/J, (26) (The Jackson Laboratory) in C57BL/6J 
background. Ccr2fl/fl and Ccr2ecKO littermates were used for all experiments. Mice expressing a 
VE-cadherin-EGFP fusion protein through a DNA construct knocked into the Cdh5 locus (27)
were obtained from D. Vestweber.
Transmigration assay 
Primary lung endothelial cells (3x104) were seeded on gelatin-coated 24-well transwell inserts 
with 8μm pores (BD) and allowed to grow to confluency. Endothelial cells were pre-incubated 
with the following inhibitors: 50 µM RS504393 (CCR2), 50 µM 2-APB (IP3-gated Ca
+
channels), 10 µM BAPTA-AM (chelating intracellular Ca2+), 1 µM ML-7 (MLCK), 5 µM H-
61152 (ROCK2), 2.5 µM Blebbistatin (myosin II ATPase) for two hours in RPMI1640/10% 
FCS medium (all inhibitors were purchased from Tocris). The first four inhibitors were used 
according to manufacturer’s recommendations (Tocris); for H-1152 and Blebbistatin we used 
concentrations as previously published (28). Upon removal of inhibitors from the endothelial 
cells MC-38GFP cells (2x104) were added in presence or absence of CD115+ monocytes 
(1x105) in RPMI1640/3% FCS. Transmigration was induced with RPMI1640/10% FCS in the 
lower chamber and terminated after 16 hours. Alternatively, MC-38GFP cells (2x104) were 
added to the upper insert with or without rhCCL2 (1 μg/ml; kindly provided by A. Kungl, 
University of Graz). The number of transmigrated MC-38GFP cells was counted using a Zeiss
AxioVision microscope (n ≥ 3).
Transendothelial electrical resistance
Transendothelial electrical resistance (TEER) was measured using Electric Cell-Substrate 
Impedance Sensing (ECIS) as reported (29). When a constant impedance of endothelial layer 
was detected (24 h post-seeding) rhCCL2 (10µg/ml) was added to cells. Impedance was 
measured every 48 seconds (ECIS-zeta system, Applied BioPhysics Inc.) for 22 hours at a 
frequency of 4000Hz while cells were continuously maintained in a humidified atmosphere at 
37°C and 5% CO2. Statistical significance was calculated by unpaired t-test. 
Preparation of cell lysates
Primary lung microvascular cells or bEnd.3 cells were stimulated with 40 ng/ml IL-1β (R&D 
Systems) for 2 hours in RPMI1640/10% FCS, and washed with PBS prior to addition of
CCL2; 100 ng/ml (R&D Systems) in RPMI1640/10% FCS for indicated times. CCR2 was 
blocked with 50 µM RS504393 inhibitor during IL-1β and CCL2 stimulation. Cells were 
scraped-off the plates in ice-cold 1xPBS, centrifuged for 5 min and lysed in 100 µl cell lysis 
buffer (20mM Tris pH 7.5, 150mM NaCl, 1mM EDTA, 1% Triton X-100) supplemented with 
7phosphatase inhibitor cocktail 3 (Sigma) and complete protease inhibitor cocktail (Roche) for 
20 min on ice. After centrifugation, cell lysates were stored at -80°C. 
Western blot
Cell lysate (20 µg) was separated on a 15% SDS-PAGE gel, transferred to a nitrocellulose 
membrane Protran 0.45 NC (GE Healthcare) and blocked with 5% BSA/TBS-T (1% Tween 
20) for 1h at RT. Primary antibodies: rabbit anti-phosphoMLC2 (Ser19) (Cell Signaling), anti-
β-catenin (Cell Signaling), anti-VE-cadherin (Abcam), and mouse anti-β-actin (Sigma) were 
incubated overnight at 4°C. After washing with TBS-T (3x), the membrane was incubated with 
a secondary antibody: HRP-linked-anti-rabbit IgG (Cell Signaling) or anti-mouse IgG, HRP-
linked (Cell Signaling) for 1h at RT. After washing with TBS-T (3x), the membrane was
developed with ECL West Dura solution (ThermoFisher Scientific) and chemiluminescent 
signal was detected using Hyperfilm ECL (GE Healthcare).
Immunoprecipitation
The endothelial cell line bEnd.3 was stimulated with 40 ng/ml IL-1β (R&D Systems) for 2h in 
RPMI1640/10%FCS. After washing with PBS, cells were incubated with 1 μg/ml rhCCL2 in 
RPMI/10%FCS for 1h. Cell lysates were prepared as mentioned above and β-catenin was 
immunoprecipitated with anti-β-catenin antibody overnight at 4°C in the presence of Protein G 
beads (GE Healthcare). Beads were washed (3x) with the lysis buffer, boiled in Laemmli buffer 
and separated on a 7.5% SDS-PAGE gel, followed by Western blotting.
Cell sorting of endothelial cells
Lungs of mice were perfused with PBS followed by digestion with Collagenase A and 
Collagenase D (2 mg/ml each, Roche) in RPMI1640/2%FCS for 1h at 37°C. The digested 
8tissue was filtered through a 100 µm cell strainer, RBC lysed and filtered again through a 40 
µm cell strainer. Resuspended cells were incubated with an Fc block (eBioscience) for 10 min 
in FACS buffer (PBS/10mM EDTA, 2% FCS), followed by incubation with antibodies: CD45-
PB, CD11b-APC-Cy7, CD31-PE-Cy7, Ly6C-FITC, Ly6G-PerCP-Cy5.5 (all from BD) for 30 
min on ice. After washing, endothelial cells (CD45-CD11b-CD31+) were sorted on a FACS 
Aria III 5L (BD). 
RNA preparation, cDNA generation and qPCR
RNeasy Mini Kit (Qiagen) was used for RNA isolation from cells in vitro and TRI Reagent 
(Sigma) was used for RNA isolation from perfused lungs. cDNA was prepared from 250 ng 
RNA using the Omniscript RT Kit (Qiagen) according to manufacturer’s instructions. Real-
time PCR was performed using SYBR Green JumpStart Taq ReadyMix kit (Sigma) with gene-
specific intron-spanning primers (Table S1) on the Mx3000P qPCR cycler (Agilent). Cycle 
conditions: 95°C for 30 sec, 60°C for 30 sec, 72°C for 30 sec. GAPDH was used as an internal 
control. 
Flow cytometry of peripheral blood and lungs
Blood was mixed with PBS/5mM EDTA and spun down. Lung tissue was digested as 
described above. After RBC lysis with PharmLyse (BD), resuspended leukocytes were 
incubated with Fc block (eBioscience) in FACS buffer for 10 min; followed by staining with
antibodies: CD45-APC-Cy7, CD11b-PE-Cy7, Ly6C-FITC, Ly6G-PerCP-Cy5.5, CD45-PerCP-
Cy5.5, CD3-APC-Cy7, CD4-FITC, CD8-PE-Cy7, CD11b-BV510, CD19-APC, NK1.1-PerCP-
Cy5.5, CD45-PB, anti-CD11b-APC-Cy7, anti-Ly6C-APC (all from BD) and CD146-PerCP-
Cy5.5 (Biolegend) for 30 min on ice. For staining of CCR2 we used MC-21 antibody (30), 
followed by goat-anti-rat-PE antibodies (BD). Data were acquired with a FACSCanto (BD), in 
some cases with CountBright absolute counting beads (Life Technologies), and analyzed by 
9FlowJo software (Tree Star).
Metastasis models
Lewis lung carcinoma cells LLC1.1 (300,000 cells) were subcutaneously (s.c.) injected into 
mice. Primary tumor was removed after 14 days and mice were terminated four weeks after 
s.c. injection. Perfused lungs were imaged and metastatic foci were counted. The primary 
tumor and the metastatic lungs were fixed and paraffin sections prepared. MC-38GFP colon 
cancer cells (300,000) or LLC1.1 cells (150,000) were intravenously injected (i.v.). MC-
38GFP injected mice were terminated after 4 weeks and LLC1.1-injected mice after 2 weeks.
Perfused lungs were imaged and metastatic foci were counted. The lungs were fixed and 
paraffin sections histologically evaluated.
Evans Blue assay
Ccr2fl/fl and Ccr2ecKO mice were s.c. injected with 300,000 LLC1.1 cells. After 14 days, 2 
mg/ml of Evans Blue solution (Sigma) was i.v. injected and the lungs perfused with PBS 30 
min later and analyzed (9).
Histology and immunohistochemistry
Tissue paraffin sections (2µm) were stained with hematoxylin/eosin or the following 
antibodies: F4/80 (Serotec), Ly6G (BD), CD31 (Abcam), CD3 (NeoMarkers), B220 (BD), 
Ki67 (NeoMarkers), cleaved-caspase-3 (BD). Staining was performed on a NEXES immune-
histochemistry robot (Ventana instruments) using an IVIEW DAB Detection Kit (Ventana) or 
on a Bond MAX (Leica). Images were digitized with a SCN400 slide scanner (Leica) and 
analyzed using Tissue IA image analysis software in a double-blind manner (Slidepath, Leica).
Tissue sections were stained simultaneously for each antigen and the signal to noise cut-off 
was manually adjusted for each antibody staining. This cut-off was applied to all samples 
within one staining group and positive signal (above the cut-off) is displayed in % of the total 
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area analyzed.
Cytokine analysis
Cytokines in lung tissue lysates (200 µg) were measured with the ProcartaPlex Mouse Panel 1 
(26-plex) kit and VEGF (10 µg lysate) with the Mouse VEGF-A Platinum ELISA kit (both 
eBioscience).
Statistical analysis
Statistical analysis was performed with the GraphPad Prism software (version 6.03). All data 
are presented as mean ±SEM and were analyzed by ANOVA with the post-hoc Bonferroni 
multiple comparison test. Analysis of two groups was performed with Mann-Whitney test 
unless stated otherwise.
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Results
Characterization of mice with endothelial-specific deletion of Ccr2
To define the function of endothelial CCR2 in controlling tumor cell extravasation, we 
made a mouse with an endothelial cell-specific deletion of Ccr2. For this purpose the VE-
cadherin-Cre mouse (26) was bred with the Ccr2fl/fl mouse (25) to generate the VE-cad-
Cre/Ccr2fl/fl mouse (hereafter Ccr2ecKO mouse). The cell-specific deletion of Ccr2 was 
confirmed by qPCR of sorted pulmonary endothelial cells (supplementary Figure 1A). We 
observed the same levels of circulating inflammatory (Ly6Chi) and patrolling (Ly6Cint) 
monocytes in Ccr2fl/fl and Ccr2ecKO mice (supplementary Figure 1B). In contrast, reduced 
numbers of Ly6Chi monocytes were detected in Ccr2-/- mice as reported previously (9, 13). 
Other circulating leukocyte subsets were not altered between Ccr2fl/fl and Ccr2ecKO littermates.
Unchanged amount of CCR2 expression was detected on inflammatory monocytes (Ly6Chi) in
the peripheral blood of Ccr2ecKO and Ccr2fl/fl mice (supplementary Figure 1C, left panel). Since 
VE-cadherin expression has been detected also in myeloid CD11b+ cells (26), we analyzed the 
expression of CCR2 in knock-in mice expressing VE-cadherin-GFP from the VE-cadherin 
genetic locus, Cdh5-EGFP (27). We observed no GFP expression in circulating Ly6Chi cells
(supplementary Figure 1C, right panel). Next, we analyzed the endothelial progenitor cells 
(CD45-CD31+CD146+) of the lungs (31). A reduced CCR2 expression was detected on 
endothelial progenitor cells from Ccr2ecKO mice when compared to Ccr2fl/fl mice (Figure 1A). 
Importantly, the level of CCR2 expression on inflammatory monocytes in Ccr2ecKO mice 
remained unaffected (supplementary Figure 1C). Overall, these data indicate that endothelial 
Ccr2 deletion does not interfere with the homeostasis of inflammatory monocytes. 
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Primary tumor growth is not altered by the absence of endothelial Ccr2
To assess the role of endothelial Ccr2 during tumorigenesis, mice were subcutaneously 
(s.c.) injected with Lewis lung carcinoma (LLC1.1) cells and spontaneous metastases to the 
lungs was determined. The tumor weight of dissected primary tumors was similar in all mouse 
genotypes after 14 days (Figure 1B). Histological analysis of primary tumors revealed no 
difference in the number of recruited F4/80+ macrophages, Ly6G+ neutrophils, CD3+ T cells, 
and B220+ B cells between Ccr2fl/fl and Ccr2ecKO mice (Figure 1C and supplementary Figure 
1D). The number of proliferating cells (Ki67+ cells), apoptotic cells (cleaved-caspase3+ cells) in 
primary tumors was identical between both mouse genotypes. To assess the effect of 
endothelial CCR2-deficiency on tumor angiogenesis, we analyzed tumor vessel density, vessel 
area and vessel permeability (Figure 1D). We observed no differences in any of the endothelial 
parameters in primary tumors irrespective of endothelial CCR2 expression suggesting that 
overall endothelial physiology, including tumor angiogenesis, is not affected by endothelial 
CCR2. 
The absence of endothelial Ccr2 attenuates lung metastases
After the primary tumor removal mice were terminated at 28 days post-tumor cell 
injection (p.i.) and spontaneous lung metastases analyzed (Figure 2A,B). We observed a
significant reduction of metastases in Ccr2ecKO mice, when compared to Ccr2fl/fl littermates. 
While the number of metastases in Ccr2fl/fl mice was comparable to wild-type (C57BL/6J) 
mice, the reduced metastases detected in Ccr2ecKO mice were comparable to Ccr2-/- mice. 
Histological analysis of lung metastases revealed no difference in the number of infiltrating 
macrophages (F4/80+ cells), neutrophils (Ly6G+), T cells (CD3+) and B cells (B220+) 
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between lungs from Ccr2ecKO or Ccr2fl/fl mice (Figure 2C, supplementary Figure 2A). 
Importantly, we found similar vascular density (CD31+ area) within the metastatic foci in both 
mouse genotypes, indicating no difference in angiogenesis (Figure 2C). The number of
proliferating cells (Ki67+ cells) and apoptotic cells (cleaved-caspase3+ cells) was equal in the 
metastatic foci of Ccr2ecKO and Ccr2fl/fl mice. 
We further tested the endothelial CCR2 requirement for metastases using intravenous 
injection of LLC1.1 and colon carcinoma cells MC-38GFP. Experimental metastases of both 
cell types was significantly reduced in Ccr2ecKO mice when compared to Ccr2fl/fl littermates 
(supplementary Figure 2B,C). These results show that the absence of endothelial Ccr2 strongly 
attenuates the generation of pulmonary metastases.
Formation of the metastatic niche in lungs remains unaltered in Ccr2
ec
KO mice
To test whether the endothelial Ccr2-deficiency influences the metastatic niche 
formation, we analyzed lungs from mice that were intravenously injected with MC-38GFP 
cells. Previous analysis has shown that LLC1.1 and MC-38GFP cells induce similar responses 
during lung metastasis (5). We observed increased recruitment of inflammatory monocytes 
(Ly6Chi cells) at 12 h p.i. in both Ccr2fl/fl and Ccr2ecKO littermates (Figure 3A), which returned 
to normal levels 24 h p.i., as reported previously for wt mice (9). The numbers and the 
recruitment kinetics of myeloid cells (CD11b+), granulocytes (Ly6G+), and Ly6Cint monocytes 
were similar between the two genotypes (supplementary Figure 3A). 
The analysis of tumor cell-induced endothelial activation revealed an increase in E-
selectin and VCAM-1 mRNA expression 12 h p.i. that was similar in both Ccr2fl/fl and 
Ccr2ecKO littermates (Figure 3B). Serum amyloid A3 (SAA3) and S100A8 have been
associated with hyperpermeable regions in metastatic lungs (20). We observed a comparable 
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increase in the serum amyloid A expressions (SAA1, SAA2 and SAA3) in sorted endothelial 
cells from lungs of Ccr2fl/fl and Ccr2ecKO littermates 12 h p.i. (Figure 3B). The cytokine
analysis in the lungs of Ccr2fl/fl and Ccr2ecKO mice at 12 h and 24 h p.i. revealed similar
kinetics of cytokine expression on protein levels (Figure 3C). Chemokines (CXCL1, CCL2, 
CCL3, CCL7) and cytokines (GM-CSF and IL-6) associated with endothelial activation and 
monocyte recruitment/activation increased at 12 h p.i., and returned to normal levels at 24 h 
p.i. irrespective of a mouse genotype. Thus, the absence of endothelial Ccr2 has no apparent 
effect on leukocyte recruitment, cytokine milieu or endothelial activation in naïve or metastatic 
lungs.
Increased vascular permeability is dependent on endothelial Ccr2 expression
To test whether the absence of endothelial Ccr2 affects the formation of a pre-
metastatic niche, we analyzed lungs of mice s.c.-injected with LLC1.1 cells at 7 and 14 days 
p.i. by flow cytometry. Increased recruitment of myeloid cells (CD11b+), granulocytes 
(Ly6G+), Ly6Cint monocytes and inflammatory monocytes (Ly6Chi) to the pre-metastatic lungs 
was detected at day 14 in both Ccr2fl/fl and Ccr2ecKO littermates (Figure 3D). Lymphoid cell 
recruitment remained the same irrespective of a mouse genotype (supplementary Figure 3B). 
Similarly, increased amounts of myeloid cell subpopulations were detected in the peripheral 
blood at day 14, which correlated with the primary tumor growth progression (supplementary
Figure 3C). 
An increase in chemokines (e.g. CXCL1, CCL7, and CCL2) in pre-metastatic lungs 
was observed with tumor growth progression but did not differ between Ccr2fl/fl and Ccr2ecKO 
mice (Figure 3E). Despite reduced metastasis in the absence of endothelial Ccr2, no changes in 
the metastatic niche of the lungs were observed. Thus, we tested whether the lung vasculature
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is altered in tumor-bearing mice at 14 days. We detected small, but significant reduction in 
vascular permeability of Ccr2ecKO mice when compared to Ccr2fl/fl littermates (Figure 3F). 
These findings indicate that the endothelial Ccr2 deficiency prevents induction of vascular 
permeability, which is required for lung metastasis.
CCL2 induces loosening of endothelial junctions and the contraction of endothelial cells
Reduced vascular permeability has been previously linked to attenuated tumor cell 
extravasation and metastasis (5, 9). Thus, we tested the capacity of tumor cells to migrate 
through pulmonary endothelial cells derived from Ccr2ecKO and Ccr2fl/fl mice. Transendothelial 
migration (TEM) of tumor cells through wild-type endothelial cells was significantly 
potentiated by the addition of monocytes (Figure 4A), as described previously (9). However, 
TEM of tumor cells was potentiated by monocytes only through endothelial cells derived from 
Ccr2fl/fl but not from Ccr2ecKO mice (Figure 4A). To identify the signaling cascade facilitating 
the CCL2-induced vascular permeability, we targeted the G-protein-coupled receptor pathway 
that is required for the actin-myosin complex activation (Figure 4B). Interestingly, the pre-
incubation of endothelial cells with inhibitors of: CCR2 (RS504393), IP3-receptor (2-APB), 
intracellular Ca2+ (BAPTA-AM), myosin light-chain kinase MLCK (ML-7), Rho-associated 
kinase ROCK (H-1152), and myosin II ATPase (Blebbistatin) significantly reduced TEM of 
tumor cells. Of note, endothelial cells pretreated with RS504393, ML-7, or H-1152 showed 
also impaired TEM of 4T1 breast cancer cells (supplementary Figure 4A). These data indicate 
that inhibition of endothelial retraction attenuates monocyte-assisted transendothelial migration 
of tumor cells. Importantly, an addition of recombinant CCL2 increased TEM of MC-38GFP 
cells also in the absence of monocytes (Figure 4C). Since MC-38GFP cells do not express 
Ccr2 (32), we tested the hypothesis that CCL2 activates endothelial CCR2 which results in 
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endothelial retraction. We measured transendothelial electrical resistance (TEER) of primary 
pulmonary endothelial cells after stimulation with CCL2. TEER of the endothelial monolayer 
decreased upon CCL2 stimulation compared to the control (Figure 4D, supplementary Figure 
4B), confirming that CCL2 stimulation triggers endothelial retraction. 
Activation of actin-myosin contraction is required for cell retraction and depends on
phosphorylation of myosin light chain 2 (pMLC2) (33). Stimulation of endothelial cells with 
CCL2 resulted in accumulation of pMLC2 (Figure 5A). The analysis of an endothelial cell line 
bEnd.3 showed that CCL2 activation induced the accumulation of pMLC2 1-2 hours after 
stimulation (Figure 5B). We observed no changes in total MLC2 expression but only an 
increase in MLC2 phosphorylation (supplementary Figure 5A). To prove that endothelial 
pMLC2 accumulation is driven by CCL2 stimulation, we treated bEnd.3 cells with a CCR2 
inhibitor that resulted in diminished phosphorylation of MLC2 (Figure 5C). Loosening of the 
endothelial barrier is caused by the dissociation of VE-cadherin/-catenin complex (34). CCL2 
stimulation of endothelial cells resulted in dissociation of the VE-cadherin/β-catenin complex 
(Figure 5D) hence confirming a direct effect of CCL2 on endothelial barrier function. CCL2 
activated bEnd.3 cells showed also reduced VE-cadherin co-localization with -catenin 
(supplementary figure 5B-C); thereby complementing the immunoprecipitation data (Figure 
5D). These data provide evidence that CCL2-driven activation of endothelial CCR2 results in
the cytoskeletal rearrangement and loosening of the endothelial cell junctions and thereby 
facilitates an efficient transendothelial migration of tumor cells. 
Discussion
Dissemination of tumor cells during metastasis is promoted by platelet- and monocyte-
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assisted extravasation from the circulation (3, 5, 9, 35). Particularly, the chemokine/chemokine 
receptor axis CCL2-CCR2 appears to be involved in several steps during metastasis including 
leukocyte recruitment, angiogenesis, immune suppression, and cancer cell extravasation (6-9, 
35). Since the systemic inhibition of CCR2/CCL2 interferes with the egress of inflammatory 
monocytes from the bone-marrow (13, 36), the observed reduced recruitment of monocytes to 
metastatic sites is rather a consequence of reduced numbers of circulating Ly6Chi cells. To 
dissect the contribution of endothelial Ccr2 from the Ccr2-dependent monocyte recruitment to 
metastasis we generated an endothelial cell-specific Ccr2 deletion mouse model (Ccr2ecKO 
mice). In this model, we observed no alteration in the numbers of circulating cells or in the 
recruitment of inflammatory monocytes to metastatic lungs. Nevertheless, a significant 
attenuation of metastasis was observed in Ccr2ecKO mice when compared to control 
littermates. Taken together, these findings suggest that the local activation of endothelial Ccr2 
is essential for tumor cell extravasation during lung metastasis. 
Endothelial CCR2 has been linked to regulation of the blood-brain-barrier vascular 
permeability during inflammation (18, 37) and to the regulation of angiogenesis (38, 39). 
Recently we have shown that endothelial CCR2 promotes metastasis by facilitating tumor cell 
extravasation (9). In this report we show that neither the primary tumor growth nor the tumor
angiogenesis were affected by the absence of endothelial CCR2, which is agreement with 
previous findings that endothelial CCR2 expression has been observed only in the brain and the 
lungs (9, 38). Notably, the absence of endothelial Ccr2 did not alter the endothelial activation
upon tumor cell challenge. 
Transendothelial migration of cells is a tightly regulated process that controls 
distribution of leukocytes throughout the organism (40). Induction of vascular permeability is 
essential for an efficient transendothelial migration of tumor cells (9, 20, 41). Enhanced 
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vascular permeability in lungs was previously associated with a Ccr2-dependent increase of 
inflammatory permeability factors SAA1+2 and SAA3 (20). We observed similar cytokine and 
chemokine levels in lungs of tumor-challenged mice of Ccr2ecKO and Ccr2fl/fl genotypes.
Although similar levels of permeability factors such as VEGF-A, SAA3 and CCL2 were 
detected in the lungs of Ccr2ecKO and Ccr2fl/fl mice, we observed impaired induction of 
vascular permeability only in Ccr2ecKO mice. These results demonstrate that endothelial CCR2 
is the regulator of tumor cell-induced lung vascular permeability. Furthermore, transendothelial 
electrical resistance was decreased by CCL2 stimulation of endothelial cells, indicating 
loosening and disassembly of endothelial intercellular junctions. Inhibition of CCR2 or the
proteins regulating the endothelial actin-myosin cytoskeleton (MLCK, ROCKII, myosin II) 
severely impaired tumor cell transendothelial migration in vitro. In endothelial cells, MLC2 
phosphorylation represents the sole regulation of myosin II ATPase activity during 
inflammation or angiogenesis (22, 23, 42-44). Indeed, CCL2 stimulation of endothelial cells 
induced phosphorylation of MLC2, which could be blocked by a CCR2 inhibitor. Presented 
data provide evidence that CCR2-mediated endothelial activation induces disassembly of 
adherens junctions thereby facilitating transendothelial migration of tumor cells. 
In conclusion, we describe a mechanism how endothelial CCR2 regulates lung 
metastasis through the activation of the actin-myosin cytoskeleton using by an endothelial cell-
specific Ccr2-deficient (Ccr2ecKO) mouse model. Translation of CCR2 inhibition into clinical 
setting will require timely and spatially defined approach, due to the homeostatic function of 
CCL2-CCR2 signaling mediating the release of monocytes from the bone marrow (36). 
Systemic inhibition of CCL2 in mouse models led to reduction of breast cancer metastasis, 
however; cessation of a treatment resulted in accelerated tumor growth due to an enhanced 
release of monocytes from the bone marrow (8). Nevertheless, targeting of CCR2 inhibitors to 
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the metastatic niche attenuated metastasis without any side effects (32, 45). Further progress in 
cell-specific targeting will show whether CCR2 targeting will be of therapeutic value. 
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Figure legends
Figure 1. Primary tumor growth was not effected by endothelial deficiency of CCR2. A) 
A) Analysis of endothelial progenitor cells (CD31+CD146+CD45-) in the lungs of naïve 
Ccr2ecKO mice and Ccr2fl/fl mice. B) Weight of primary subcutaneous LLC1.1 tumors at time 
of resection (14 days after implantation); ns = not significant. C) Representative images of 
primary tumors stained with CD31, F4/80, cl-Casp3 and Ki67 Abs together with histological 
analysis, respectively. Bar = 50 µm. D) Representative images of primary tumors from 
Ccr2ecKO and Ccr2fl/fl mice, respectively, stained with anti-CD31 (white) to analyze vascular 
density (nuclear staining with DAPI = blue). The analysis of vessel density and the vessel area 
revealed no difference between mice of both genotypes. Vessel permeability in tumors was 
determined using intravenous injection of dextran-FITC 1 h prior to termination. Cryosections 
of the tumors were analyzed for the dextran-FITC. Bar = 30 µm.
Figure 2. Endothelial Ccr2 is required for lung metastasis. A) Spontaneous lung metastasis 
in C57BL/6, Ccr2fl/fl, Ccr2ecKO, and Ccr2-/- mice 28 days after subcutaneous injection of 
LLC1.1 cells. **; p<0.01; ns = not significant. B) Representative images of lungs from mice 
analyzed in panel A. C) Representative images of pulmonary metastasis stained with anti-CD31 
(vasculature) and anti-F4/80 (macrophages) antibodies. Proliferating cells (Ki67 staining) and 
apoptotic cells (cleaved Caspase 3 staining; cl-Casp3) were evaluated. The edge of a metastatic 
lesion is presented. The histological analysis of metastatic foci only was performed. Bar = 50 
µm. 
Figure 3. Initiation of the pre-metastatic niche is not impaired in Ccr2
ec
KO mice. A)
25
Flow cytometry analysis of inflammatory monocytes (CD45+CD11b+Ly6G-Ly6Chi) recruited to 
the lungs at 12 and 24 h after i.v. MC-38GFP injection of Ccr2fl/fl and Ccr2ecKO mice. 
Untreated naïve mice (n) were used as controls. B) Endothelial cells (CD45-CD11b-CD31+) 
sorted from lungs of Ccr2fl/fl and Ccr2ecKO mice 12 h after i.v. MC-38GFP injection or 
untreated (naive) mice were analyzed for the expression levels of E-selectin, VCAM-1, 
SAA1+2 and SAA3 (n = 3-6) C) Amounts of cytokines in perfused lung homogenates of 
Ccr2fl/fl and Ccr2ecKO mice at 12 and 24 h after i.v. MC-38GFP injection. Untreated mice 
(control) were used as controls. D) Flow cytometry analysis of myeloid cells (CD45+CD11b+), 
granulocytes (CD45+CD11b+Ly6G+), Ly6Cint monocytes (CD45+CD11b+LyG-Ly6Cint), and 
inflammatory monocytes (CD45+CD11b+Ly6G-Ly6Chi) recruited to lungs of mice s.c.-injected 
with LLC1.1 cells after 7 and 14 days. E) Amounts of cytokines detected in lung homogenates 
of mice s.c.-injected with LLC1.1 cells after 7 and 14 days. F) Lung vascular permeability 
assay of Ccr2fl/fl and Ccr2ecKO mice 14 days after s.c. injection of LLC cells, including 
representative macroscopic images. Statistical significance in panels B, D, E and F was 
assessed using unpaired t-test; *; p<0.05; **; p<0.01; ***; p<0.001.
Figure 4. CCL2 stimulation induces endothelial retraction and transendothelial 
migration of tumor cells. A) Transendothelial migration of MC-38GFP cells through lung 
endothelial cells isolated from C57BL/6 wild-type (BL6), Ccr2fl/fl and Ccr2ecKO mice, either in 
the absence (-) or in the presence of CD115+ monocytes (+).The number of migrated tumor 
cells was counted per view field (pvf) and is normalized to the control (+ monocytes); ns; not 
significant; *; p<0.05. B) Transendothelial migration of MC-38GFP cells in the absence (-) or 
in the presence of CD115+ monocytes (+). Endothelial cells from C57BL/6 mice (ECs) were 
pre-treated with RS-504393 (50 µM), 2-APB (50 µM), BAPTA-AM (10 µM), ML-7 (1 µM), 
H-1152 (5 µM), and Blebbistatin (2.5 µM) for two hours and washed out of the inhibitor prior 
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to addition of tumor cells +/- monocytes. DMSO as a diluent of inhibitors was used as a 
control. Tumor cell migration was analyzed as described in panel A. ***; p<0.001. C) 
Transendothelial migration of MC-38GFP cells (without monocytes) only in presence of 
rhCCL2 (1 μg/ml) compared to a control. **; p<0.01. D) TEER measurement of primary lung 
endothelial cells upon stimulation with rhCCL2 (10 µg/ml). TEER values for rhCCL2-treated 
and control samples were normalized to 1 at the start of stimulation (0 h). Black bars = 
control; open bars = CCL2-treated; n = 4; *; p<0.05; other time points showed no significant
differences.
Figure 5. CCL2 stimulation of endothelial cells induces phosphorylation of myosin-light 
chain 2 and loosening of endothelial barrier. A) Immune-detection of phosphorylated 
MLC2 (pMLC2) in the lysates of primary pulmonary endothelial cells after stimulation with 
CCL2 (100 ng/ml) for one and two hours. Per lane 20 µg of protein lysate were loaded; β-actin 
served as a loading control. B) Detection of pMLC2 in bEnd.3 endothelial cells after 
stimulation with CCL2 (100 ng/ml). β-actin serves as a loading control. C) Immune-detection 
of pMLC2 in lysates of bEnd.3 endothelial cells stimulated with CCL2 (100 ng/ml) for 30 min, 
1 h, and 2 h, in the absence or presence of the CCR2 inhibitor RS504393 (50 µM). Per lane 20 
µg of protein lysate were loaded; β-actin served as a loading control. D) Immunoprecipitation 
of β-catenin and detection of co-immune-precipitated VE-cadherin in bEnd.3 cell lysates 
stimulated with rhCCL2 (1 μg/ml) for 1 h. Quantification of immune-precipitated VE-cadherin 
in ratio to -catenin (lower panel) n=4, *; p<0.05.
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